GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bright Minds Biosciences DRUG · USD

Health Care · US listing · 🇺🇸 United States

Compare

24.11

+4.83%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bright Minds Biosciences

Its shares trade under the ticker DRUG. It has been listed since 22 March 2021.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Mar 2021
Head office
400 N ABERDEEN ST SUITE 900, CHICAGO, IL, 60642
Incorporated in
A1
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bright Minds Biosciences Inc. has a strong portfolio of 5-HT2 Receptors for epilepsy and neuropsychiatric disorders.
  • BMB-101 has completed phase 1 trials and is in phase 2 for developmental epileptic encephalopathies.
  • The company collaborates with Firefly Neuroscience for EEG data analysis in the BREAKTHROUGH study.

Weaknesses

  • The company has no products approved for market yet in the United States.
  • BMB-105 is a 5-HT2C agonist targeting Prader Willi Syndrome with no clinical data available.
  • BMB-201 and BMB-202 are still in development for neuropsychiatric indications.

Opportunities

  • The company's focus on severe diseases offers potential for high unmet medical needs in the US market.
  • BMB-101's phase 2 trials could lead to new treatments for absence epilepsies.
  • Collaboration with Firefly Neuroscience may enhance data analysis for clinical studies.

Threats

  • The US regulatory environment for biotech products remains complex and challenging.
  • Competition in the epilepsy treatment market is growing with multiple new therapies entering the pipeline.
  • The company's reliance on phase 2 trials for BMB-101 increases development risk.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.